Clinical trials: Physical activity
Advanced Soft Tissue Sarcoma
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece
This non-interventional study aims primarily at assessing the clinical effectiveness and the impact of the therapy on cancer-related symptoms and patients' HRQoL.
- Trial name
- beYOND-STS (NCT02618122)
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Genesis Pharma S.A.
Multiple Myeloma
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
The study consists of three parts: Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple…
- Trial name
- DynaMMic-1 (NCT05714839)
- Testing
- Belantamab, Belantamab mafodotin, Pomalidomide
- Where
- 44 sites in United States, Argentina and 11 more
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Influenza
Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation
The main purpose of this study is to assess the potential exposure of neonates to oseltamivir during lactation by examining oseltamivir concentrations in maternal blood, urine, and breast milk in breastfeeding women who are…
- Trial name
- NCT01130636
- Testing
- Oseltamivir
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Pharmahungary Group
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
Schizophrenia
Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia
The purpose of this study is to determine whether cognitive impairment associated with schizophrenia is attenuated by add-on roflumilast administration to second generation antipsychotics (SGA) in participants with stable…
- Trial name
- NCT02079844
- Testing
- Roflumilast, Second generation antipsychotic
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Takeda
Cancer, Advanced Solid Tumor
StrataPATH™ (Precision Indications for Approved Therapies)
StrataPATH™ is a non-randomized, open-label trial designed to explore efficacy and safety of multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided patient populations.
- Trial name
- StrataPATH (NCT05097599)
- Testing
- lorlatinib, encorafenib + binimetinib, talazoparib
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Strata Oncology
Premature Ejaculation
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)
A Phase 2b, 8-week, double-blind, placebo-controlled, parallel group study to evaluate the effect of 3 different dose levels of IX-01 on IELT and patient-reported outcome in men with lifelong PE.
- Trial name
- NCT03055806
- Testing
- IX-01 400 mg, IX-01 800 mg, IX-01 1200 mg
- Where
- 29 sites in United States
- Volunteers
- 239 people
- Sponsor
- Ixchelsis Limited
Breast Cancer, Gastric Cancer
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of zanidatamab in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT04276493
- Testing
- Zanidatamab, Docetaxel, Tislelizumab
- Where
- 21 sites in China, South Korea and 1 more
- Volunteers
- 71 people
- Sponsor
- BeiGene
Smoldering Multiple Myeloma
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
The purpose of this study is to evaluate the anti-tumor activity, safety and pharmacology of two dose regimens (0.2 and 2 mg/kg)of IPH2101 in patients with Smoldering Multiple Myeloma.
- Trial name
- KIRMONO (NCT01222286)
- Testing
- IPH2101
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Innate Pharma
Metastatic Castration Resistant Prostate Cancer
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
The treatment regimen will consist of 4 doses of FPI-2265
- Trial name
- TATCIST (NCT05219500)
- Testing
- FPI-2265
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- Fusion Pharmaceuticals Inc.
Advanced Solid Malignancies
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced…
- Trial name
- NCT03394144
- Testing
- AZD9150, Durvalumab
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Postoperative Pain, Acute
PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)
The goal of this clinical trial is to evaluate the analgesic activity of PF614 (an oral oxycodone prodrug extended-release analgesic) for control of postsurgical pain in subjects scheduled for abdominoplasty surgery.
- Trial name
- NCT06602271
- Testing
- PF614 capsule
- Where
- 3 sites in United States
- Volunteers
- 320 people
- Sponsor
- Ensysce Biosciences
Solid Tumor
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate…
- Trial name
- NCT06234098
- Testing
- AT-1965 Liposome Injection
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alyssum Therapeutics
Chronic Pain
Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
This is a proof of concept study to measure the effect of Wearable Health Technology (WHT), including the Apple Watch, iPhone, Pain App and Provider Dashboards on important clinical outcomes in patients treated for chronic pain.
- Trial name
- NCT03299556
- Testing
- WHT
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Purdue Pharma LP
Chronic Pain, Knee Pain Chronic
HFIT Versus TENS Study for Chronic Low Back and Knee Pain
A high-frequency impulse therapy (HFIT) device (Enso, San Francisco, CA) is a portable device for the treatment of musculoskeletal pain.
- Conditions
- Chronic Pain, Knee Pain Chronic, Back Pain, Low
- Trial name
- NCT05821530
- Testing
- HFIT, TENS, Control
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- Hinge Health, Inc
Non-Small Cell Lung Cancer
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
This was a Phase II, open-label, single-arm, single-stage, multicenter trial in patients with relapsed non-small cell lung cancer (NSCLC), with the objective of assessing the activity of the combination of erlotinib and…
- Trial name
- PENGUIN (NCT00855894)
- Testing
- Pertuzumab, Erlotinib
- Where
- 10 sites in United States, Australia
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.
- Trial name
- NCT05438329
- Testing
- DB-1305/BNT325, Pembrolizumab, BNT327
- Where
- 93 sites in United States, China and 1 more
- Volunteers
- 1,123 people
- Sponsor
- DualityBio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.